El-Rayes B - Search Results

1

An update on the multimodality of localized rectal cancer.

Artac M, Korkmaz L, El-Rayes B, Philip PA. Artac M, et al. Crit Rev Oncol Hematol. 2016 Dec;108:23-32. doi: 10.1016/j.critrevonc.2016.10.004. Epub 2016 Oct 26. Crit Rev Oncol Hematol. 2016. PMID: 27931837 Review.

2

Pancreatic cancer: the evolving role of systemic therapy.

Adsay NV, El-Rayes BF, Philip PA. Adsay NV, et al. Expert Opin Pharmacother. 2001 Dec;2(12):1939-47. doi: 10.1517/14656566.2.12.1939. Expert Opin Pharmacother. 2001. PMID: 11825326 Review.

3

Developments in the systemic therapy of pancreatic cancer.

el-Rayes BF, Shields AF, Vaitkevicius V, Philip PA. el-Rayes BF, et al. Cancer Invest. 2003;21(1):73-86. doi: 10.1081/cnv-120016406. Cancer Invest. 2003. PMID: 12643012 Review.

4

Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer.

El-Rayes BF, Zalupski MM, Shields AF, Vaishampayan U, Heilbrun LK, Jain V, Adsay V, Day J, Philip PA. El-Rayes BF, et al. J Clin Oncol. 2003 Aug 1;21(15):2920-5. doi: 10.1200/JCO.2003.03.022. J Clin Oncol. 2003. PMID: 12885810 Clinical Trial.

5

A phase II study of carboplatin and paclitaxel in esophageal cancer.

El-Rayes BF, Shields A, Zalupski M, Heilbrun LK, Jain V, Terry D, Ferris A, Philip PA. El-Rayes BF, et al. Ann Oncol. 2004 Jun;15(6):960-5. doi: 10.1093/annonc/mdh230. Ann Oncol. 2004. PMID: 15151955 Free article. Clinical Trial.

6

Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.

El-Rayes BF, Zalupski MM, Manza SG, Rusin B, Ferris AM, Vaishampayan U, Heilbrun LK, Venkatramanamoorthy R, Shields AF, Philip PA. El-Rayes BF, et al. Cancer Chemother Pharmacol. 2008 Feb;61(2):283-9. doi: 10.1007/s00280-007-0472-1. Epub 2007 Apr 12. Cancer Chemother Pharmacol. 2008. PMID: 17429629 Free PMC article. Clinical Trial.

7

Protein kinase C: a target for therapy in pancreatic cancer.

El-Rayes BF, Ali S, Philip PA, Sarkar FH. El-Rayes BF, et al. Pancreas. 2008 May;36(4):346-52. doi: 10.1097/MPA.0b013e31815ceaf7. Pancreas. 2008. PMID: 18437080

8

Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer.

Ali S, Banerjee S, Ahmad A, El-Rayes BF, Philip PA, Sarkar FH. Ali S, et al. Mol Cancer Ther. 2008 Jun;7(6):1708-19. doi: 10.1158/1535-7163.MCT-08-0354. Mol Cancer Ther. 2008. Retraction in: Mol Cancer Ther. 2018 Oct;17(10):2266. doi: 10.1158/1535-7163.MCT-18-0522 PMID: 18566242 Free PMC article. Retracted.

9

Exploitation of protein kinase C: a useful target for cancer therapy.

Ali AS, Ali S, El-Rayes BF, Philip PA, Sarkar FH. Ali AS, et al. Cancer Treat Rev. 2009 Feb;35(1):1-8. doi: 10.1016/j.ctrv.2008.07.006. Epub 2008 Sep 7. Cancer Treat Rev. 2009. PMID: 18778896 Review.

10

Protein kinases C isozymes are differentially expressed in human breast carcinomas.

Ali S, Al-Sukhun S, El-Rayes BF, Sarkar FH, Heilbrun LK, Philip PA. Ali S, et al. Life Sci. 2009 May 22;84(21-22):766-71. doi: 10.1016/j.lfs.2009.03.007. Epub 2009 Mar 24. Life Sci. 2009. PMID: 19324060 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

295 results

Search Page

Filters